Novel Non-Hallucinogenic 5-HT2A Agonists May Advance Depression Treatment, Preclinical Study Suggests
Scientists at the University of California, Davis have developed a new class of psychedelic-inspired compounds that activate a key brain receptor associated with depression treatment without producing hallucinatory-like effects in animal studies. The findings could contribute to the development of safer therapies for depression and other psychiatric disorders.
The study, published in the Journal of the American Chemical Society, focused on compounds that activate the serotonin 5-HT2A receptor. This receptor plays an important role in brain plasticity and is the primary target of classic psychedelics such as LSD and psilocybin, both of which are being investigated as rapid-acting treatments for depression.
Researchers Used Light to Create New Drug Candidates
The UC Davis researchers used ultraviolet (UV) light to transform simple amino acids into previously unknown molecules with potential therapeutic properties. They first combined several amino acids with tryptamine, a naturally occurring metabolite derived from the amino acid tryptophan that forms the structural backbone of many psychedelic compounds.
When these hybrid molecules were exposed to ultraviolet light, the energy triggered chemical rearrangements that produced entirely new molecular structures. The researchers then used computational modeling to predict how strongly approximately 100 of these compounds would bind to the serotonin 5-HT2A receptor.
Based on these predictions, five promising compounds were selected for laboratory testing. Their ability to activate the receptor ranged from 61% to 93%, with the most active compound, designated D5, functioning as a full agonist capable of producing the receptor's maximum biological response.
Full Receptor Activation Without Hallucinatory-Like Effects
Because D5 strongly activated the same receptor targeted by psychedelic drugs, the researchers expected it to produce the head twitch response in mice—a behavioral measure widely used in preclinical research as an indicator of psychedelic-like activity.
Instead, the findings were unexpected. Despite fully activating the 5-HT2A receptor, mice treated with D5 did not exhibit the characteristic head twitch response associated with hallucinogenic signaling. The compound appeared to suppress, rather than promote, behaviors typically linked to psychedelic effects.
Co-authors Joseph Beckett and Trey Brasher said the study identifies a previously unknown chemical scaffold capable of interacting with serotonin signaling pathways in novel ways. According to the researchers, discovering an entirely new scaffold with these properties is uncommon in psychedelic drug research and may influence the future design of psychiatric medications.
Potential Implications for Depression Treatment
The findings support a growing scientific hypothesis that the therapeutic effects of psychedelic compounds—including enhanced brain plasticity and rapid improvements in mood—may be separable from the profound alterations in perception that characterize the psychedelic experience. If this proves true, researchers may eventually be able to develop fast-acting antidepressants without requiring patients to undergo hallucinogenic experiences.
Current psychedelic-assisted therapies remain under clinical investigation and typically require extensive psychological preparation, supervised treatment sessions, and follow-up care because of their powerful subjective effects. Non-hallucinogenic psychedelic analogues could potentially offer a more practical and scalable treatment approach if they demonstrate similar therapeutic benefits in future studies.
The UC Davis researchers now plan to investigate how D5 interacts with other serotonin receptors and intracellular signaling pathways. Their goal is to understand why a compound that fully activates the 5-HT2A receptor does not produce hallucinatory-like effects and whether similar molecules can safely promote the brain plasticity associated with treatments for depression, post-traumatic stress disorder (PTSD), and addiction.
The study involved collaborators from the Medical College of Wisconsin, the University of California, San Diego, and HepatoChem Inc. Funding was provided by the U.S. National Institutes of Health and the Source Research Foundation.
Although the findings are promising, the research remains at the preclinical stage. Human clinical trials have not yet begun, and the researchers note that many experimental neuropsychiatric compounds ultimately fail during clinical development before reaching patients.
